EDSA — Edesa Biotech, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-06-10.
Performance
Technicals
Others in Healthcare
Measured signals that fired on EDSA
| date | signal | measured base rate |
|---|---|---|
| 2026-06-09 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-28 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
| 2026-04-21 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-03-09 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-03-03 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-03 | Nijhawan Pardeep Chief Executive Officer | Grant or award | 5.3K | 0.00 | 0 |
| 2026-07-02 | Nijhawan Pardeep Chief Executive Officer | Grant or award | 3.4K | 0.00 | 0 |
| 2026-06-16 | Nijhawan Pardeep Chief Executive Officer | Grant or award | 153.6K | 5.21 | 800.0K |
| 2026-06-01 | Nijhawan Pardeep Chief Executive Officer | Grant or award | 1.7K | 0.00 | 0 |
| 2026-05-27 | Chypyha Joan Director | Grant or award | 19.0K | 0.00 | 0 |
| 2026-05-27 | Liu Da David Director | Grant or award | 19.0K | 0.00 | 0 |
| 2026-05-27 | Sistilli Carlo Director | Grant or award | 19.0K | 0.00 | 0 |
| 2026-05-27 | Olson Charles V Director | Grant or award | 19.0K | 0.00 | 0 |
| 2026-05-27 | Nijhawan Pardeep Chief Executive Officer | Grant or award | 96.9K | 0.00 | 0 |
| 2026-05-27 | Brooks Michael J President | Grant or award | 64.6K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Velan Capital Investment Management LP | 4.3M | 827.5K |
| Rubric Capital Management LP | 3.6M | 687.5K |
| PERCEPTIVE ADVISORS LLC | 2.9M | 563.2K |
| JANE STREET GROUP, LLC | 605.2K | 115.7K |
| VANGUARD CAPITAL MANAGEMENT LLC | 449.6K | 86.0K |
| GEODE CAPITAL MANAGEMENT, LLC | 403.0K | 77.1K |
| VANGUARD FIDUCIARY TRUST CO | 201.1K | 38.4K |
| STATE STREET CORP | 198.6K | 38.0K |
| COMMONWEALTH EQUITY SERVICES, LLC | 183.1K | 35.0K |
| Scientech Research LLC | 159.7K | 30.5K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Edesa Biotech, Inc. (EDSA) filed form 8-K · 2026-08-20 · SEC EDGAR
- Edesa Biotech prices $25M equity offering · 2026-08-20
- Edesa Biotech stock tumbles on public offering launch · 2026-08-19
- Edesa Biotech, Inc. (EDSA) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about EDSA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →